Glutamate ionotropic receptor NMDA type subunit 2D mRNA (GRIN2D mRNA)

GRIN2D mRNA is the messenger RNA transcript that encodes the GluN2D subunit of the N-methyl-D-aspartate (NMDA) receptor, an essential ionotropic glutamate receptor involved in excitatory signaling and synaptic plasticity (UniProt: Q14957). The GluN2D subunit is particularly prominent during early brain development and in specific adult brain regions like the basal ganglia, where it influences neuronal excitability and circuit maturation. In the context of human disease, gain-of-function mutations in the GRIN2D gene lead to developmental and epileptic encephalopathy (DEE), characterized by treatment-resistant seizures and profound developmental delays (PubMed: 31430173). Because traditional NMDA receptor antagonists often lack the necessary subunit specificity or cause significant side effects, the GRIN2D mRNA has become a focal point for precision genetic therapies. Antisense oligonucleotides (ASOs) are being developed to target this mRNA, utilizing RNase H-mediated degradation to reduce the expression of the overactive GluN2D protein (PubMed: 34634023). This mRNA-directed approach offers a way to specifically downregulate the pathogenic subunit while potentially sparing other NMDA receptor subtypes, providing a targeted strategy for managing genetically defined epilepsies. Monitoring efficacy typically involves tracking seizure reduction and neurodevelopmental milestones in patients identified through genetic screening for GRIN2D variants.

Other names

NR2D mRNAN-methyl-D-aspartate receptor subunit 2D mRNAGluN2D mRNAGlutamate receptor ionotropic, NMDA 2D mRNA

Antisense oligonucleotides target the GRIN2D mRNA through complementary base pairing, which typically recruits RNase H to cleave the RNA-DNA heteroduplex, leading to the degradation of the mRNA transcript and a subsequent reduction in the translation of the GluN2D protein subunit.